Investigational compound formerly called amycretin (NNC0487-0111); no approved commercial brand verified. It is a single molecule, unlike the two-drug CagriSema combination.
24.3% reported weight loss · 1.1% loss with placebo · 36 weeks
Escalation up to 60 mg once weekly
Adults aged 18–55 with BMI 27.0–39.9, without diabetes
Early-phase estimated mean from dose-escalation cohort; not verified as a treatment-policy estimand Investigational; AMAZE phase 3 obesity programme initiated in Q1 2026
Safety context
Frequent GI effects; substantial withdrawals, many unrelated to treatment-emergent adverse events.
Limitations: 125 is whole multipart trial, not top-dose cohort. Small early-phase safety study; no phase 3 obesity outcome yet.
Status in this atlas: Investigational compound formerly called amycretin (NNC0487-0111); no approved commercial brand verified. It is a single molecule, unlike the two-drug CagriSema combination.
Investigational compound formerly called amycretin (NNC0487-0111); no approved commercial brand verified. It is a single molecule, unlike the two-drug CagriSema combination.
Novo Nordisk · Developer of oral and subcutaneous formulations of this single-molecule GLP-1/amylin receptor agonist.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule
Also called amycretin. One peptide activates GLP-1, amylin and calcitonin receptors. Oral and injected forms share these targets.
Structure not yet verified
Structure not verified
Also called amycretin. One peptide activates GLP-1, amylin and calcitonin receptors. Oral and injected forms share these targets.
Shown: Peptide drug
An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.
The Q2 2026 presentation reports that the obesity program began in Q1 2026 and describes oral AMAZE 9 separately. This is a dated sponsor status disclosure; individual formulation timelines differ.
Registry first posting, not actual initiation: 8,500 planned adults with established ASCVD and overweight/obesity, with or without stable type 2 diabetes. Phase 3 placebo comparison on four-point cardiovascular events; not yet recruiting. October 26 start and September 16, 2030 completion are estimates; no event benefit established.
New trial studies tolerability when switching from tirzepatide to zenagamtide
A 60-person phase 1 switching study from maintenance tirzepatide to zenagamtide is registered, not yet recruiting after an estimated October 8 start. Primary endpoint is adverse-event count through day 57; no combination dosing, randomized continuing-tirzepatide comparison or efficacy superiority is established.
Zenagamtide switching study now records recruitment and an actual start
The tirzepatide-to-zenagamtide study resolves its elapsed October start estimate, while remaining a small uncontrolled tolerability study. September 7, 2028 estimated primary/final completion; no public-result date. The registry reports actual October 8 study start; October 16 is the posted update date.